FIGS, Inc. has set its sights on achieving an adjusted EBITDA margin of 9.0% to 9.5% for the full year 2025. However, the company expects a slight decline in net revenues due to less promotional activity and a possible reduction in active customer numbers, according to a report from Nasdaq.
To counteract any potential impact from U.S. tariffs on Chinese imports, FIGS has strategically shifted its supply chain. Notably, the company sources its finished goods from countries outside China. Insider Monkey reports that FIGS also prioritizes operational flexibility, allowing it to adapt quickly to changes in trade policies while ensuring high product standards for healthcare professionals.
Financially, FIGS ended 2024 with a robust balance sheet, boasting over $268 million in cash reserves and no debt. This strong financial position supports the company's ability to invest in growth strategies and fulfill shareholder returns, reinforcing its commitment to weathering economic shifts and maintaining long-term stability.